Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 609-619

  Kobelt, Dennis ^a   Aumann, Jutta ^a,b   Schmidt, Manuel ^c   Wittig, Burghardt ^d   Fichtner, Iduna ^a   Behrens, Diana ^a   Lemm, Margit ^a   Freundt, Greta ^a,b   Schlag, Peter M ^a,b   Walther, Wolfgang ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MOLOGEN AG   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cancer; Gene therapy; Melanoma; Nonviral gene transfer; TNF alpha

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; EFFECTOR CASPASE; INITIATOR CASPASE; TUMOR NECROSIS FACTOR ALPHA; VINDESINE; ANTINEOPLASTIC AGENT; DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA VECTOR; ENZYME ACTIVATION; GENE EXPRESSION; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MIDGE DNA VECTOR; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SENSITIZATION; TRANSGENE; XENOGRAFT; ANIMAL; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; PATHOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DNA; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MELANOMA; MICE; TRANSFECTION; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA; VINDESINE;

EID: 84899491872     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.019     Document Type: Article

References (51)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756.
2. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res. 2006, 12:2353s-2358s.
3. Baban D.F., Seymour L.W. Control of tumour vascular permeability. Adv. Drug Deliv. Rev. 1998, 34:109-119.
4. Baluk P., Yao L.C., Feng J., Romano T., Jung S.S., Schreiter J.L., Yan L., Shealy D.J., McDonald D.M. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J.Clin. Invest. 2009, 119:2954-2964.
5. Barbour A.P., Thomas J., Suffolk J., Beller E., Smithers B.M. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann. Surg. Oncol. 2009, 16:3463-3472.
6. Belizario J.E., Tilly J.L., Sherwood S.W. Caffeine potentiates the lethality of tumour necrosis factor in cancer cells. Br. J. Cancer 1993, 67:1229-1235.
7. Bigger B.W., Tolmachov O., Collombet J.M., Fragkos M., Palaszewski I., Coutelle C. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J.Biol. Chem. 2001, 276:23018-23027.
8. Boretti F.S., Leutenegger C.M., Mislin C., Hofmann-Lehmann R., Konig S., Schroff M., Junghans C., Fehr D., Huettner S.W., Habel A., Flynn J.N., Aubert A., Pedersen N.C., Wittig B., Lutz H. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 2000, 14:1749-1757.
9. Chabot S., Orio J., Schmeer M., Schleef M., Golzio M., Teissie J. Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery. Gene Ther. 2013, 20:62-68.
10. Chen Z.Y., He C.Y., Ehrhardt A., Kay M.A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression invivo. Mol. Ther. 2003, 8:495-500.
11. Chen Z.Y., He C.Y., Meuse L., Kay M.A. Silencing of episomal transgene expression by plasmid bacterial DNA elements invivo. Gene Ther. 2004, 11:856-864.
12. Chen Z.Y., Riu E., He C.Y., Xu H., Kay M.A. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol. Ther. 2008, 16:548-556.
13. Choi Y., Jeon Y.H., Kang J.H., Chung J.K., Schmidt M., Kim A.C. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. Int J cancer 2007, 120:1942-1950.
14. Darquet A.M., Cameron B., Wils P., Scherman D., Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997, 4:1341-1349.
15. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7213-7218.
16. de Wilt J.H., Soma G., ten Hagen T.L., Kanou J., Takagi K., Nooijen P.T., Seynhaevel A.L., Eggermont A.M. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats. Anticancer Res. 2000, 20:3491-3496.
17. Deroose J.P., Eggermont A.M., van Geel A.N., de Wilt J.H., Burger J.W., Verhoef C. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann. Surg. Oncol. 2012, 19:627-635.
18. Deroose J.P., Eggermont A.M., van Geel A.N., Verhoef C. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr. Opin. Oncol. 2011, 23:183-188.
19. Deroose J.P., Grunhagen D.J., van Geel A.N., de Wilt J.H., Eggermont A.M., Verhoef C. Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br. J. Surg. 2011, 98:1573-1580.
20. Eggermont A.M. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 1998, 18:3899-3905.
21. Eggermont A.M., Schraffordt Koops H., Lienard D., Kroon B.B., van Geel A.N., Hoekstra H.J., Lejeune F.J. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J.Clin. Oncol. 1996, 14:2653-2665.
22. Galling N., Kobelt D., Aumann J., Schmidt M., Wittig B., Schlag P.M., Walther W. Intratumoral dispersion, retention, systemic biodistribution, and clearance of a small-size tumor necrosis factor-alpha-expressing MIDGE vector after nonviral invivo jet-injection gene transfer. Hum. Gene Ther. Part B. Methods 2012, 23:264-270.
23. Guiet C., Silvestri E., De Smaele E., Franzoso G., Vito P. c-FLIP efficiently rescues TRAF-2-/- cells from TNF-induced apoptosis. Cell Death Differ. 2002, 9:138-144.
24. Hohenberger P., Latz E., Kettelhack C., Rezaei A.H., Schumann R., Schlag P.M. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Ann. Surg. Oncol. 2003, 10:562-568.
25. Hou Y., Zhang H., Miranda L., Lin S. Serious overestimation in quantitative PCR by circular (supercoiled) plasmid standard: microalgal pcna as the model gene. PloS One 2010, 5:e9545.
26. Jaques D.P., Coit D.G., Brennan M.F. Major amputation for advanced malignant melanoma. Surg. Gynecol. Obstet. 1989, 169:1-6.
27. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clinicians 2011, 61:69-90.
28. Jin S., Ray R.M., Johnson L.R. TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G928-G937.
29. Kedar E., Rutkowski Y., Leshem B. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells. Cancer Immunol. Immunother. CII 1992, 35:63-68.
30. Kobelt D., Schleef M., Schmeer M., Aumann J., Schlag P.M., Walther W. Performance of high Quality minicircle DNA for invitro and invivo gene transfer. Mol. Biotechnol. 2013, 53:80-89.
31. Lasek W., Wankowicz A., Kuc K., Feleszko W., Giermasz A., Jakobisiak M. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Oncology 1996, 53:31-37.
32. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998, 10:573-580.
33. Mayrhofer P., Schleef M., Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol. Biol. 2009, 542:87-104.
34. Menon C., Ghartey A., Canter R., Feldman M., Fraker D.L. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann. Surg. 2006, 244:781-791.
35. Mocellin S., Rossi C.R., Pilati P., Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005, 16:35-53.
36. Mouawad R., Sebert M., Michels J., Bloch J., Spano J.P., Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit. Rev. Oncol./Hematol. 2010, 74:27-39.
37. Regenass U., Muller M., Curschellas E., Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer. 1987, 39:266-273.
38. Schakowski F., Gorschluter M., Buttgereit P., Marten A., Lilienfeld-Toal M.V., Junghans C., Schroff M., Konig-Merediz S.A., Ziske C., Strehl J., Sauerbruch T., Wittig B., Schmidt-Wolf I.G. Minimal size MIDGE vectors improve transgene expression invivo. InVivo 2007, 21:17-23.
39. Schakowski F., Gorschluter M., Junghans C., Schroff M., Buttgereit P., Ziske C., Schottker B., Konig-Merediz S.A., Sauerbruch T., Wittig B., Schmidt-Wolf I.G. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol. Ther. 2001, 3:793-800.
40. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., Bayol N., Gillen M., Chu K., Rasmussen C., Rasmussen H., Kufe D., Weichselbaum R., Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J.Clin. Oncol. 2004, 22:592-601.
41. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., Kong W.P., Nabel G.J., Gomez P.L. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol. Sci. 2006, 91:610-619.
42. Stein U., Walther W. Cytokine-mediated reversal of multidrug resistance. Cytotechnology 1998, 27:271-282.
43. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3740-3745.
44. Takai D., Jones P.A. The CpG island searcher: a new WWW resource. In Silico Biol. 2003, 3:235-240.
45. Walther W., Arlt F., Fichtner I., Aumann J., Stein U., Schlag P.M. Heat-inducible invivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol. Cancer Therapeut. 2007, 6:236-243.
46. Walther W., Minow T., Martin R., Fichtner I., Schlag P.M., Stein U. Uptake, biodistribution, and time course of naked plasmid DNA trafficking after intratumoral invivo jet injection. Hum. Gene Ther. 2006, 17:611-624.
47. Walther W., Siegel R., Kobelt D., Knosel T., Dietel M., Bembenek A., Aumann J., Schleef M., Baier R., Stein U., Schlag P.M. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin. Cancer Res. 2008, 14:7545-7553.
48. Walther W., Stein U., Fichtner I., Voss C., Schmidt T., Schleef M., Nellessen T., Schlag P.M. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol. Biotechnol. 2002, 21:105-115.
49. Walther W., Stein U., Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int. J. Cancer. 1995, 61:832-839.
50. Wolff J.A., Budker V. The mechanism of naked DNA uptake and expression. Adv. Genet. 2005, 54:3-20.
51. Xu J., Zhou J.Y., Wu G.S. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006, 66:10092-10099.